Largest U.S. study confirms safety of local vaginal estrogen therapy for younger survivors of endometrial cancer

Largest U.S. study finds low-dose vaginal estrogen does not increase cancer recurrence risk in younger endometrial cancer survivors, improving menopause care.

By: AXL Media

Published: Mar 4, 2026, 9:38 AM EST

Source: The information in this article was sourced from The Menopause Society

Addressing the quality-of-life gap in cancer survivorship

As early detection and targeted treatments improve, the number of women surviving endometrial cancer has risen significantly. However, the treatments required—such as hysterectomies, radiation, and chemotherapy—often induce abrupt, early menopause. This transition is typically associated with severe genitourinary symptoms, including vaginal dryness, painful intercourse, and urinary issues, which rarely improve without medical intervention. Historically, survivors were steered away from hormone treatments due to fears of cancer recurrence, leaving them with non-hormonal options that often provide limited relief.

The safety of localized vs. systemic therapy

The primary barrier to prescribing estrogen to endometrial cancer survivors has been the "black box" warning associated with systemic hormone therapy. However, low-dose vaginal estrogen therapy (ET) differs from systemic options because its effects are localized, with minimal absorption into the bloodstream. A new study published in Menopause, the journal of The Menopause Society, sought to provide evidence-based clarity on this distinction. By analyzing electronic health records and insurance claims for more than 2,800 women aged 18 to 51, researchers were able to track the long-term outcomes of survivors who utilized local ET.

Findings: No elevated risk of recurrence

The study followed survivors for an average treatment duration of 1.88 years. The results showed that survivors who utilized local, low-dose vaginal ET did not face an increased risk of endometrial cancer recurrence compared to those who avoided the treatment. Despite the clear benefits, the study found that only about 5.6% of younger survivors currently initiate this therapy, likely due to lingering fears among both patients and providers. As the largest study of its kind in the U.S., these results provide a strong scientific foundation for expanding treatment options for a population that is growing as the incidence of early-onset endometrial cancer increases.